Navigation Links
Scientists tackle the mystery of white-nose syndrome in bats
Date:6/4/2009

KNOXVILLE -- The mysterious disease that has killed more than 90 percent of wintering bats in some caves and mines from Vermont to Virginia during the last three years has raised numerous questions about the nature of the disease and how to control it.

Leading experts in the fields of bat physiology, fungal ecology, ecotoxicology, disease and environmental modeling, among others, will gather at a workshop at the National Institute for Mathematical and Biological Synthesis (NIMBioS), June 29-July 1, at the University of Tennessee, Knoxville, to explore the disease and to develop solutions to manage it. Representatives from relevant state and federal agencies and other organizations will also attend.

The affliction has been given the name White-Nose Syndrome (WNS) due to its distinctive white fungus growing on the muzzles and other body parts of infected bats. More than a half million bats have died in the last three years due to the disease. Although the cause is unknown, the pathogen is most likely a cold climate fungus. Scientists do not know if the fungus is the sole cause of the bat deaths, or if it is merely an opportunistic pathogen, taking advantage of immune systems weakened by another biological or chemical agent.

It is unclear how WNS spreads, but it is likely transmitted from bat to bat. Other evidence suggests that humans transport the fungus from infected sites to clean sites on clothing and equipment.

The purpose of the meeting is to determine the present knowledge of the disease and to develop predictive models to determine how and under what conditions the disease might spread. Ultimately, the models would be used to help devise appropriate management strategies for controlling it.

Tom Hallam, workshop co-organizer and professor of ecology and evolutionary biology at UT Knoxville, said so far two management strategies have been proposed to contain the spread of the disease. The first is to eliminate hu
'/>"/>

Contact: Catherine Crawley
ccrawley@nimbios.org
865-974-9350
National Institute for Mathematical and Biological Synthesis
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Scientists examine perceptions of risk and the spread of disease
2. Scientists discover new genetic immune disorder in children
3. Scientists uncover mode of action of enzyme linked with several types of cancer
4. Scientists unravel the mystery of white-nose syndrome
5. Seventy-three scientists elected to the American Academy of Microbiology
6. Scientists examine human behavior and the threat of disease
7. Singapore scientists elected into National Academy of Sciences
8. Scientists explain how death receptors designed to kill our cells may make them stronger
9. Caltech scientists reveal how neuronal activity is timed in brains memory-making circuits
10. Scientists develop a new HIV microbicide -- and a way to mass produce it in plants
11. City rats loyal to their hoods, scientists discover
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6